GlassScriptPhysician profile
Thomas O Obisesan
NPI 1295894426
$40,506.49
in general payments reported to CMS, 2019-2025
11 companies · $80.00 in 2025
The $80.00 reported for 2025 was less than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2021: $2,234 · 2022: $5,726 · 2023: $11K · 2024: $21K · 2025: $80.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Travel and Lodging: $3,517 · Food and Beverage: $1,417 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,375.00 |
| Travel and Lodging | $3,517.15 |
| Food and Beverage | $1,416.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15,297.85 | 2022-2024 | Kisunla |
| Eisai INC. | $14,385.87 | 2022-2024 | |
| F. Hoffmann-La Roche Ag | $4,845.16 | 2024-2025 | |
| Eli Lilly and Company | $3,283.58 | 2021-2022 | |
| Genentech USA, INC. | $1,800.00 | 2022 | |
| Grifols Biologicals LLC | $686.92 | 2019 | |
| Stryker Corporation | $148.93 | 2022 | |
| Ani Pharmaceuticals, INC. | $32.73 | 2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $25.45 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Obisesan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.